Back to News
Market Impact: 0.4

Why is Stellantis stock sliding today?

Analyst InsightsAnalyst EstimatesCompany FundamentalsCorporate Guidance & OutlookGeopolitics & WarConsumer Demand & Retail
Why is Stellantis stock sliding today?

Stellantis shares fell 1.3% to €4.633 after two bearish analyst downgrades. JPMorgan cut its rating to Neutral from Overweight and slashed its price target from €10.00 to €6.00, arguing the benefits from lower component costs won’t reach product launches for ~14 months, pushing meaningful recovery to FY2027–FY2028. HSBC also downgraded to Reduce from Hold, citing U.S. dealer inventories rising to 93 days (about 120k units above a year earlier) and 19 2026 recalls covering ~2.5M units, leaving investors skeptical of the turnaround as the stock trades near its 52-week low.

Analysis

The market is not pricing a one-quarter miss; it is pricing a delayed cash-flow reset. When procurement savings sit 12+ months away and the balance sheet is still carrying inventory and recall friction, every extra quarter of weak turns increases incentive spending, warranty reserves, and the probability that the eventual recovery arrives after the multiple has already compressed further. That makes STLA look less like a cyclical rebound and more like a stalled turnaround until there is hard evidence of unit discipline. Relative winners are the OEMs with tighter dealer stocks, cleaner quality metrics, and less need to buy volume through discounting. In autos, that usually means names like TM and HMC, while the losers are not just STLA shareholders but also Tier-1 suppliers and logistics firms exposed to downstream order cuts if dealers keep trimming replenishment schedules. Elevated energy and geopolitical risk also matters here: it raises the consumer’s monthly ownership cost and tends to force additional incentives on mass-market brands first, which hits margins before it shows up in headline unit data. The contrarian case is that the stock is already close to trough pricing, so a reflex rally is possible if management can prove U.S. inventory is normalizing faster than expected and recall expense is peaking. What would falsify the short thesis is a clear reduction in days supply below roughly 80, stable warranty reserves, and no further downward revisions to margin guidance. Absent that, the setup is a classic value trap: downside is slower-moving, but it can persist for several quarters as the market waits for FY27 evidence that may never fully arrive.